Chemical Compound

Dabrafenib

CAS Registry Number 1195765-45-7
Back to search Request a Quote
Dabrafenib chemical structure
Primary Record

Dabrafenib

In stock
4,669 g
Purity
99.6 %
CAS
1195765-45-7

Compound Identifiers & Properties

CAS
1195765-45-7
PubChem CID
44462760
SMILES
CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
Canonical SMILES
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1

Names & Synonyms

  • Dabrafenib
  • Tafinlar
  • 1195765-45-7
  • dabrafenibum
  • Dabrafenib mesylate
  • Dabrafenib?
  • Dabrafenib (GSK2118436)
  • dabrafenib mesilate
  • GSK2118436A
  • UNII-QGP4HA4G1B
  • Dabrafenib (USAN)
  • GSK2118436
  • QGP4HA4G1B
  • Dabrafenib (Free Base)
  • Dabrafenib (Standard)
  • Dabrafenib [USAN:INN]
  • Tube719
  • DABRAFENIB [MI]
  • RefChem:58040
  • DABRAFENIB [INN]
  • DABRAFENIB [USAN]
  • DABRAFENIB [VANDF]
  • D05ROI
  • D0BO9V
  • GSK-2118436
  • DABRAFENIB [WHO-DD]
  • Dabrafenib (BRAF inhibitor)
  • GSK-2118436A
  • MFCD17215684
  • CHEBI:75045
  • MLS006011052
  • SCHEMBL806377
  • C23H20F3N5O2S2
  • DTXSID20152499
  • GSK 2118436
  • GTPL6494
  • orb1307175
  • 1195765-45-7 (free base)
  • CHEMBL2028663
  • DTXCID8074990
  • SCHEMBL29350038
  • SCHEMBL29353365
  • GSK2118436B
  • BRAF Inhibitor GSK2118436
  • DABRAFENIB, KB-57246
  • L01XE23
  • QCR-129
  • BFSMGDJOXZAERB-UHFFFAOYSA-N
  • GLXC-90044
  • HMS3656D12
  • HMS3672G05
  • HMS5081L17
  • AMY10291
  • AOB87722
  • API01001
  • BCP09341
  • EX-A1320
  • KS-000005OR
  • ABP001006
  • BBF-04018
  • BDBM50428286
  • EBC-11470
  • FD5028
  • GSK 2118436A
  • GSK 2118436B
  • HY-14660R
  • MSK169306
  • NSC764134
  • NSC800083
  • ZINC68153186
  • (GSK2118436) pound notDabrafenib
  • AKOS024463285
  • AKOS032950004
  • ACN-041315
  • CCG-264736
  • CS-0692
  • Dabrafenib Mesylate (GSK-2118436)
  • DB08912
  • FA65034
  • NSC-764134
  • NSC-800083
  • SB13355
  • SDCCGSBI-0654477.P001
  • NCGC00346716-01
  • NCGC00346716-02
  • NCGC00346716-14
  • 4CA-0431
  • AC-25889
  • AS-19634
  • BC297817
  • BP-43637
  • CID:44462760
  • DA-62632
  • HY-14660
  • SMR004702844
  • SID:162064811
  • AB0087834
  • N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
  • A3347
  • B1407
  • NS00040699
  • S2807
  • SW219503-1
  • Y1871
  • J3.135.454D
  • A11381
  • D10064
  • W-5688
  • AB01565833_02
  • A852141
  • C561627
  • Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-
  • N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
  • Q3011604
  • BRD-K09951645-001-06-8
  • BRD-K09951645-001-08-4
  • BRD-K09951645-001-11-8
  • BRD-K09951645-066-01-2
  • 1195768-06-9
  • N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
  • N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
  • BENZENESULFONAMIDE, N-(3-(5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1-DIMETHYLETHYL)-4-THIAZOLYL)-2-FLUOROPHENYL)-2,6-DIFLUORO-
  • Dabrafenib, 98%, a mutant BRAFV600 specific inhibitor - 100MG 100mg
  • N-(3-(5-(2-AMINOPYRIMIDIN-4-YL)-2-TERT-BUTYL-1,3-THIAZOL-4-YL)-2-FLUOROPHENYL)-2,6-DIFLUOROBENZENESULFONAMIDE
  • N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfo
  • N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide
  • N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
  • 2,6-Difluoro-N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]benzenesulfonamide
  • 2,6-Difluoro-N-[3-[5-(2-amino-4-pyrimidinyl)-2-tert-butyl-4-thiazolyl]-2-fluorophenyl]benzenesulfonamide
  • 2,6-Difluoro-N-[3-[5-(2-aminopyrimidine-4-yl)-2-tert-butylthiazole-4-yl]-2-fluorophenyl]benzenesulfonamide
  • 689-166-9
  • N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
  • N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzene-1-sulfonamide
  • N-(3-(5-(2-Aminopyrimidine-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
  • N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide
  • N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide; Dabarefenib; GSK 2118436; Tafinlar; GSK 2118436A
  • N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
  • N-[3-[5-(2-Amino-4-pyrimidinyl)-2-tert-butyl-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
  • N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-thiazol-4-yl]-2-fluoro-phenyl]-2,6-difluoro-benzenesulfonamide
  • N-{3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl}-2,6- difluorobenzenesulfonamide
  • N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
  • N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide
  • P06